Tolga Tanguler: Yes, no, I mean, just to add one quick point on that is, if you look at the clinical practice of how physicians actually diagnose and treat this disease, it starts with the suspicion, and the suspicion usually doesn’t necessarily start whether you have cardiac manifestation of diseases or the polyneuropathy manifestations of this disease. Eventually, based on the data we have obviously both with ONPATTRO and AMVUTTRA, physicians are absolutely looking for neuropathic manifestations to make sure that they can treat this as effectively as possible. And the disease is treated always through multidisciplinary centers. So at the end of the day, physicians don’t just look at the patients with whether they have CM, PN or mixed genotype. They go through how to best understand the disease and then through a multidisciplinary approach, try to treat the disease in the best possible way and based on the indications of the products.
Christine Lindenboom: Thanks, Tolga. Next question.
Operator: One moment for our next question. Our next question comes from the line of Gena Wang with Barclays. You may proceed.
Gena Wang: Thank you. Sorry. I will ask another AMVUTTRA question. So, regarding the subgroup, the top line you will share? Will you share, are the subgroup information, both primary and secondary endpoint, and also in the scenario that HELIOS-B is positive, will you also at some point lower a AMVUTTRA price to be competitive compared to say, tafamidis and other tools [ph]?
Yvonne Greenstreet: I’ll just take the pricing question. I mean, I think it’s really too early for us to talk about kind of specific kind of pricing approaches here, just to remind you. And Tolga touched on this in his introductory remarks. I mean, we will obviously bear in mind our patient access principles, and we’ll be making sure that we have considerations around access and affordability to make sure that patients are going to be able to benefit from what we hope will be a medicine with a very robust profile. Pushkal, do you want to take the question on?
Pushkal Garg: Yes, I mean, Gena, I don’t know that there’s a lot more that I can add in terms of the remarks that I made and then Yvonne has reiterated in terms of the top line. We plan again to speak to the, primary endpoint, which is now in the two populations, the secondaries across those populations, safety. And we’ll make some commentary around subgroups, but it’s hard to give you anything more than that today. That’s our plan.
Gena Wang: All right, thanks, Pushkal.
Yvonne Greenstreet: Next question.
Operator: One moment for our next question. Our next question comes from the line of Salveen Richter with Goldman Sachs. You may proceed.
Unidentified Analyst: Thanks for taking our question. This is Tommy Yan [ph] for Salveen. So beyond the top line, and regarding data analyses presented on the forward, would you include detailed analysis on AMVUTTRA impact in patients who were defined as past progressors given the unmet need in this population and just to see how AMVUTTRA could benefit these patients? Thank you.
Tolga Tanguler: Yes, Tommy, I think what you’re asking about is actually deeper cuts of the data, and certainly this is going to be a very rich and large data set. So you can imagine that we’ll be looking at this in a lot of different ways. But again, I think, I guess the primary thing I would focus on is the fact that we will have a pretty robust data set, both with the drug treated as a monotherapy and in patients who came in on tafamidis. And I think you have to ask yourself, why would someone who’s on a drug decide to enroll in a three plus year clinical trial? And that really indicates that they are obviously not satisfied with how they’re feeling or functioning at that moment in time. And so I think our combination group, where we do have a sizable portion of patients, and we’ll be able to report on that, will help address part of your question.
Operator: One moment for our next question. Thank you. Our next question comes from the line of Mike Ulz with Morgan Stanley. You may proceed.
Mike Ulz: Good morning. Thanks for taking the question. Maybe just a follow-up on the launch preparation question. Just curious what you guys have sort of done so far in preparing for a potential launch, and then what are the sort of remaining steps that will be triggered by positive data from HELIOS-B?
Yvonne Greenstreet: That’s a great question. I’m going to pass it on to Tolga. And I just want to kind of, underscore how pleased I am actually with, the commercial footprint that we built. And I think, if you look at our performance with respect to AMVUTTRA in patients with polyneuropathy I think we’re really demonstrating strong growth momentum here, and I’m just really pleased with how the commercial organization is focusing on meeting the needs of patients in this indication, I have no doubt that we’ll do the same, assuming a possibility of HELIOS-B and being able to launch into the cardiomyopathy indication. But Tolga, you may have some specific comments about how we’re thinking about launching into what I think is going to be actually one of the most exciting categories.
Tolga Tanguler: You took a little bit of wind away Yvonne, because I was just going to highlight the fact that despite competition, the growth of our TTR franchise now in the U.S. is 35% year-over-year, which is quite important, and I think is an important indicator of the growth momentum that we built. Look, we have a great brand, great data in polyneuropathy, which clearly demonstrated 90% market share in Europe and Japan, where we actually do compete with tafamidis and the same indication. And now in the U.S., we’re essentially established a very important stronghold in centers that actually treat both cardiomyopathy and polyneuropathy. We obviously strictly promote our polyneuropathy indication, but the asset, the product, is now known both by cardiologists, who also tend to diagnose this disease, as well as neurologists.
Therefore, we’re really well positioned to launch pending the HELIOS-B outcome results, which is going to be obviously very critical. And as Yvonne indicated, we’re going to play to win. We have a great footprint, a well informed and trained organization, not just in the customer facing side, but also patient facing side. And we also are very cognizant that this opportunity is going to be tenfold of the opportunity that we currently have. Therefore, we’re going to make the right appropriate adjustments and make sure that we are clearly differentiated and more importantly, set ourselves so that the product is affordable and accessible to the patients.
Yvonne Greenstreet: Thanks, Tolga. I think we’ve got a. Sorry, I think …
Operator: We’re taking one more question. That’s my understanding. And our last question comes from the line of Whitney Ijem with CG. You may move ahead.
Whitney Ijem: Hey guys, thanks for taking the question. And I’m just going to throw one non-HELIOS-B question in there, because there will be catalysts after that. So can you help remind us, I guess, for Part B of the ALN-APP study, what we should expect to see later this year, particularly around any biomarker or imaging data?
